Bristol-Myers Squibb stock holds mid-range as analysts trim price target after trial halt

Published on 09/21/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, sitting about 8 percent below its 52-week high. A recent trial halt and a small cut in a key analyst price target keep risk and valuation in focus ahead of the October 29, 2026 earnings report.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb stock (ISIN US1078421011) closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, placing the large cap biopharmaceutical name solidly between its 52-week low of USD 42.53 and high of USD 68.64 and roughly 8 percent below the upper end of that range.

Analyst trim and trial halt shape the near-term story

According to Chosun Biz on September 21, 2026, Bristol-Myers Squibb decided to discontinue development of the acute myeloid leukemia treatment candidate BMS-986497 (also known as ORM-6151), leading to the termination of a USD 180 million asset transfer agreement signed with Orum Therapeutics in 2023.

As Ad-hoc-news reported on September 19, 2026, B of A Securities analyst Tim Anderson maintains a Buy rating on Bristol-Myers Squibb but has cut his price target to USD 66 from USD 67, keeping the new target about USD 2.94 above the latest closing price of USD 63.06.

The modest one dollar trim in the price target signals a cautious reaction to pipeline and competitive dynamics without a wholesale shift in the positive rating, and the combination of a terminated oncology asset and a still-supportive analyst stance underlines that risk for Bristol-Myers Squibb is concentrated in specific projects rather than the entire portfolio.

Stock performance and market positioning

Data from CNBC show that Bristol-Myers Squibb shares closed at USD 63.06 on September 18, 2026, after gaining 0.35 percent during that session, with an after-hours indication of USD 63.02 and volume near 31.9 million shares.

Per Ad-hoc-news on September 20, 2026, the company’s 52-week trading range runs from a low of USD 42.53 to a high of USD 68.64, implying that the September 18, 2026 close stands about USD 20.53 above the low and USD 5.58 below the high.

According to CompaniesMarketCap on September 20, 2026, Bristol-Myers Squibb’s market capitalization was reported at USD 128.81 billion, a roughly 15.8 percent increase compared with its level at the start of 2026.

For investors, the combination of a year-to-date gain estimated at a little more than 17 percent and a share price still below the 52-week high suggests that Bristol-Myers Squibb stock is viewed as a moderately valued large cap in the pharmaceutical sector, with scope for further upside if upcoming results and pipeline news are favorable.

Guidance and fundamental backdrop

According to StocksDownUnder, Bristol-Myers Squibb has issued guidance for 2026 revenue in a range of USD 49 billion to USD 50 billion, setting a baseline for how the market evaluates its growth trajectory over the current fiscal year.

The same overview notes that consensus estimates for fiscal year 2027 point to revenue of roughly USD 48.2 billion and normalized earnings per share of 5.63 dollars, so the 2027 revenue projection sits about USD 0.8 billion below the midpoint of the company’s 2026 guidance while earnings per share expectations support the case for substantial cash generation.

Relative to the company’s current market capitalization of about USD 128.81 billion as of September 20, 2026, the revenue guidance range implies that Bristol-Myers Squibb trades at around 2.6 times the midpoint of expected 2026 sales, a valuation level that places it in a mid-range position among diversified biopharma peers with mature portfolios and evolving pipelines.

Earnings date and analyst sentiment

Per Ad-hoc-news on September 20, 2026, Bristol-Myers Squibb is scheduled to report financial results for the third quarter of 2026 on October 29, 2026, with the earnings call set for 8:00 a.m. Eastern Time.

According to Zacks on September 21, 2026, Bristol-Myers Squibb currently carries a Zacks Rank of 2, corresponding to a Buy rating, and has returned about 16.5 percent so far in 2026, indicating that the stock has outperformed many peers in the medical sector over the same period.

As summarized by Investing.com on September 17, 2026, the average 12-month analyst price target for Bristol-Myers Squibb stands at USD 66.71, with a high estimate of USD 82 and a low estimate of USD 40, keeping the mean target about USD 3.65 above the September 18, 2026 closing price.

The mix of a Buy recommendation from Zacks, a slightly reduced but still supportive price target from B of A Securities, and an aggregate target in the mid-USD 60s reflects a broadly constructive but not euphoric stance on Bristol-Myers Squibb stock, with the upcoming third-quarter earnings release on October 29, 2026 likely to be a key test of whether the company can deliver on its 2026 revenue guidance and pipeline milestones.

Stock level and investor perspective

As of the close on September 18, 2026, Bristol-Myers Squibb stock traded at USD 63.06 on the New York Stock Exchange in United States dollars, within a 52-week range of USD 42.53 to USD 68.64, leaving the shares mid-range in their recent band and offering investors a balance between realized year-to-date gains and potential future catalysts.